title: Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers.
abstract: The inhibition of digestive lipases by the antiobesity drug Orlistat along with lipolysis levels and fecal fat excretion were measured in healthy humans. Orlistat was found to be a powerful gastric lipase inhibitor, achieving 46.6--91.4% enzyme inhibition and thus greatly reducing gastric lipolysis of solid and liquid meals (11--33% of respective controls). Gastric lipase inhibition by Orlistat was extremely fast (half-inhibition time < 1 min). Duodenal lipolysis was reduced significantly by Orlistat given with the solid meal (32.6--37.6% of controls) but was only slightly reduced by Orlistat given with the liquid meal (74.5--100% of controls). Human pancreatic lipase (HPL) inhibition was found to be high (51.2--82.6%), however, regardless of the meal. These paradoxical results were explained when in vitro lipolysis experiments were performed. The rates of HPL inhibition by Orlistat were found to be similar with both types of meals (half-inhibition time 5--6 min), but the preemulsified triglycerides of the liquid meal were rapidly hydrolyzed by HPL before the enzyme was significantly inhibited by Orlistat. With the solid meal, the rate of hydrolysis of the meal triglycerides by HPL was slower than the rate of HPL inhibition by Orlistat. As predicted from the previous results, the effects of Orlistat on fat excretion levels were found to be much greater with the solid (40.5--57.4% of ingested fat) than with the liquid (4.2--18.8%) test meal.
authors.affiliation: Laboratoire de Lipolyse Enzymatique, Centre National de la Recherche Scientifique, Institut de Biologie Structurale et Microbiologie, F-13402 Marseille Cedex 20, France. carriere@ibsm.cnrs-mrs.fr
authors.forename: F
authors.initials: F
authors.lastname: Carrière
authors.forename: C
authors.initials: C
authors.lastname: Renou
authors.forename: S
authors.initials: S
authors.lastname: Ransac
authors.forename: V
authors.initials: V
authors.lastname: Lopez
authors.forename: J
authors.initials: J
authors.lastname: De Caro
authors.forename: F
authors.initials: F
authors.lastname: Ferrato
authors.forename: A
authors.initials: A
authors.lastname: De Caro
authors.forename: A
authors.initials: A
authors.lastname: Fleury
authors.forename: P
authors.initials: P
authors.lastname: Sanwald-Ducray
authors.forename: H
authors.initials: H
authors.lastname: Lengsfeld
authors.forename: C
authors.initials: C
authors.lastname: Beglinger
authors.forename: P
authors.initials: P
authors.lastname: Hadvary
authors.forename: R
authors.initials: R
authors.lastname: Verger
authors.forename: R
authors.initials: R
authors.lastname: Laugier
mesh_terms: D000328:Adult; D019440:Anti-Obesity Agents / Q000008:administration & dosage*; D004041:Dietary Fats / Q000008:administration & dosage / Q000493:pharmacokinetics; D004383:Duodenogastric Reflux / Q000378:metabolism; D004386:Duodenum / Q000378:metabolism; D005260:Female; D005750:Gastric Juice; D005753:Gastric Mucosa / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007441:Intubation, Gastrointestinal; D007783:Lactones / Q000008:administration & dosage*; D008049:Lipase / Q000037:antagonists & inhibitors*; D008066:Lipolysis / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy / Q000378:metabolism; D000077403:Orlistat; D010179:Pancreas / Q000378:metabolism; D010189:Pancreatic Juice
chemical_list: D019440:Anti-Obesity Agents; D004041:Dietary Fats; D007783:Lactones; D000077403:Orlistat; D008049:Lipase